mesoporous polydopamine nanoparticle vaccine

Mesoporous polydopamine nanoparticle vaccine is an experimental nanovaccine platform designed to induce antigen-specific immune tolerance, particularly for the treatment of autoimmune diseases such as multiple sclerosis. The formulation consists of a mesoporous polydopamine (mPDA) nanoparticle with high reactive oxygen species (ROS)-scavenging properties, loaded with disease-relevant autoantigen peptides. Upon intravenous administration, the autoantigen-loaded mPDA nanoparticles promote the generation of tolerogenic dendritic cells that present peptide epitopes while expressing low levels of co-stimulatory molecules. This leads to the induction of peripheral regulatory T-cells (Tregs), which suppress autoreactive CD4+ T-cells and inflammatory antigen-presenting cells in the central nervous system. In preclinical models mimicking multiple sclerosis, this approach prevented disease development and promoted recovery from paralysis. The platform is being explored for broader application in other autoimmune diseases where delivery of specific autoantigen peptides is beneficial[1].

Other names

mesoporous polydopamine nanovaccinemPDA nanovaccinemesoporous polydopamine nanoparticle-based tolerogenic vaccine